This site is intended for Healthcare professionals only.

Roche’s Tecentriq wins priority review in U.S for treatment of lung cancer


Roche’s Tecentriq wins priority review in U.S for treatment of lung cancer

ZURICH: Roche’s Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.

Wednesday’s announcement comes after Roche in September said patients with untreated extensive-stage SCLC, where cancer has spread, lived a median 12.3 months after getting Tecentriq plus chemotherapy, compared to 10.3 months for those on just chemotherapy.

Also Read: Roche-AbbVie cancer drug, Venclexta gets accelerated FDA approval



Source: Reuters
0 comment(s) on Roche’s Tecentriq wins priority review in U.S for treatment of lung cancer

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted